A 70-year-old woman’s advanced lung cancer treatment transformed after genomic testing revealed a MET exon 14 skipping mutation. This ‘driver mutation’ guided oncologists to a personalized, targeted therapy, leading to a positive response and recovery. This case highlights how understanding a tumor’s molecular makeup revolutionizes cancer care, offering hope beyond conventional methods.
